Kidney Neoplasms Clinical Trial
Official title:
Evaluation of Complex Renal Cystic Lesions With Contrast Enhanced Ultrasound (CEUS) and Functional MRI Versus the Gold Standard: Computer Tomography (CT)
NCT number | NCT02371551 |
Other study ID # | 84/14 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 19, 2014 |
Est. completion date | June 30, 2018 |
Verified date | August 2019 |
Source | University Hospital Inselspital, Berne |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary concern in complex renal cysts (CRC) with malignant potential is the accurate
diagnosis and characterization. Patients with CRC have to undergo frequent imaging
surveillance (every 6-12 Mo), in which the progression suggests a neoplastic process. The
gold standard for establishing diagnosis and necessity for surgical intervention (i.e.
partial nephrectomy) is conventional computer tomography (CT) imaging. Its main drawback is
the radiation dose to the body and intravenous contrast media administration, which has a
risk of nephrotoxicity.
Magnetic resonance imaging (MRI) with special functional sequences (fMRI) and
contrast-enhanced ultrasonography (CEUS) allow measuring tissue blood flow and perfusion
characteristics without ionizing radiation or nephrotoxic contrast media. To compare the
diagnostic accuracy, sensitivity and specificity of CEUS/functional MRI versus the gold
standard CT, 60 patients with CRC will be evaluated using all these 3 modalities. The main
hypothesis is that fMRI and CEUS have equal accuracy with CT regarding diagnosis and
classification of CRC lesions.
Status | Completed |
Enrollment | 52 |
Est. completion date | June 30, 2018 |
Est. primary completion date | October 20, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion Criteria: - Age > 18 years old - Written informed consent - A complicated renal cyst (Bosniak category > II cyst or hemorrhagic cyst) or lesion > 1 cm im max. transverse diameter who will undergo standard renal CT imaging - Stable renal function (GFR> 30 ml/min/1.73 m2) Exclusion Criteria - Pregnancy - History of allergic reaction to contrast agents - Refusal to adhere to follow-up - Recent pyelonephritis - Acute kidney injury (AKI stage = 1) - Other individuals especially in need of protection (according to the Swiss Academy of Medical Sciences) |
Country | Name | City | State |
---|---|---|---|
Switzerland | Dep. of Nephrology, Hypertension and Clinical Pharmacology, Bern University Hospital | Bern |
Lead Sponsor | Collaborator |
---|---|
University Hospital Inselspital, Berne |
Switzerland,
Balci NC, Semelka RC, Patt RH, Dubois D, Freeman JA, Gomez-Caminero A, Woosley JT. Complex renal cysts: findings on MR imaging. AJR Am J Roentgenol. 1999 Jun;172(6):1495-500. — View Citation
Bosniak MA. Diagnosis and management of patients with complicated cystic lesions of the kidney. AJR Am J Roentgenol. 1997 Sep;169(3):819-21. — View Citation
Curry NS, Cochran ST, Bissada NK. Cystic renal masses: accurate Bosniak classification requires adequate renal CT. AJR Am J Roentgenol. 2000 Aug;175(2):339-42. — View Citation
Nicolau C, Bunesch L, Sebastia C. Renal complex cysts in adults: contrast-enhanced ultrasound. Abdom Imaging. 2011 Dec;36(6):742-52. doi: 10.1007/s00261-011-9727-8. Review. — View Citation
Schneider AG, Hofmann L, Wuerzner G, Glatz N, Maillard M, Meuwly JY, Eggimann P, Burnier M, Vogt B. Renal perfusion evaluation with contrast-enhanced ultrasonography. Nephrol Dial Transplant. 2012 Feb;27(2):674-81. doi: 10.1093/ndt/gfr345. Epub 2011 Jun 20. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CRC classification according to CT-finding based on Bosniak criteria or until surgical intervention | 1 year | ||
Secondary | Diagnostic accuracy of CEUS and fMRI based on the progression of CRC according to CT-finding and Bosniak classification throughout visit 1-2 | 1 year | ||
Secondary | Diagnostic accuracy of CEUS and fMRI based on surgical extraction and histopathological evaluation of the resected mass | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00678392 -
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
|
Phase 3 | |
Not yet recruiting |
NCT03129724 -
Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
|
N/A | |
Terminated |
NCT01413607 -
The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy
|
Phase 4 | |
Terminated |
NCT00091611 -
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
|
Phase 1 | |
Terminated |
NCT02439008 -
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
|
N/A | |
Completed |
NCT01688999 -
Cabozantinib for Advanced Urothelial Cancer
|
Phase 2 | |
Recruiting |
NCT05184504 -
Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
|
||
Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
Terminated |
NCT01712685 -
Imaging Studies of Kidney Cancer Using 18F-VM4-037
|
Phase 2 | |
Terminated |
NCT00816686 -
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
|
Phase 1 | |
Completed |
NCT00537056 -
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
|
N/A | |
Completed |
NCT00076011 -
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00226980 -
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
Recruiting |
NCT03062410 -
Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma
|
N/A | |
Completed |
NCT02924922 -
Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A |